There are 2867 resources available
1007P - Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC
Presenter: Arianna Marinello
Session: Poster session 14
1008P - Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
Presenter: Enriqueta Felip
Session: Poster session 14
1009P - Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib
Presenter: Sai-Hong Ou
Session: Poster session 14
1010P - Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics
Presenter: Gorka Ruiz de Garibay
Session: Poster session 14
1011P - MET and NF2 alterations confer early resistance to first-line alectinib treatment in ALK-rearranged non-small cell lung cancer
Presenter: Jie Hu
Session: Poster session 14
1012P - Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer
Presenter: Kaiwen Wang
Session: Poster session 14
1013P - Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster session 14
1014P - Resistance landscape to almonertinib in EGFR-mutated NSCLC
Presenter: mi Tian
Session: Poster session 14
1016P - GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies
Presenter: Olivier Bylicki
Session: Poster session 14